Emisphere Technologies, Inc. (OTCBB: EMIS), a commercial stage, specialty pharmaceutical company, is currently preparing to launch its first prescription product, oral Eligen B12, in the United States. Beyond Eligen B12, the company employs its proprietary Eligen Technology to create new oral formulations of therapeutic agents. Emisphere is also currently partnered with global pharmaceutical companies for the development of new orally delivered therapeutics. For more information, visit the company’s website at www.emisphere.com.
Emisphere Technologies, Inc. (EMIS) Presents at Rodman & Renshaw Conference
Previous Article
Next Article
Search Articles
Latest Articles
- FAVO Capital Inc. (FAVO): When Private Credit Meets Real Estate Collateralization
- AI and the Copper Conundrum: How Trilogy Metals Inc. (NYSE American: TMQ) (TSX: TMQ) Fits into the Supply Equation
- Silvercorp Metals Inc. (NYSE-A/TSX: SVM) El Domo Environmental License Upheld as Ecuador’s Constitutional Court Dismisses Final Challenge
- NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Seeks FDA Ban on Toxic Ketamine Preservative
- MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option